skip to main content

Prostate Cancer

A new approach to target an 'undruggable' prostate cancer driver

Date Visible: 
Thursday, March 23, 2017 - 12:00

When small-molecule inhibitors proved elusive, researchers developed a novel strategy: Using large molecule peptides to target a common prostate cancer driver. It may provide a path for developing new therapies against a challenging target.

Michigan Medicine opens first prostate cancer risk clinic in the nation

Date Visible: 
Wednesday, March 1, 2017 - 14:00
It’s well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations – along with a handful of others – and aggressive prostate cancer.

Prostate cancer treatment rates drop, reflecting change in screening recommendations

Date Visible: 
Monday, January 9, 2017 - 16:45

As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds.

The PSA and beyond: An update on prostate cancer biomarkers

There is perhaps no hotter topic in prostate cancer treatment today than the use of prostate cancer biomarkers. To learn more about them, we posed a few questions to Todd Morgan, M.D., a surgeon in the U-M Multidisciplinary Urologic Oncology Clinic.

Pages